AstraZeneca (NYSE:AZN) issued its quarterly earnings data on Thursday. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.38, Briefing.com reports. The firm had revenue of $5.34 billion during the quarter, compared to analyst estimates of $5.26 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The company’s revenue for the quarter was down 14.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 EPS. AstraZeneca updated its FY 2018 guidance to $3.30-3.50 EPS and its FY18 guidance to $3.30-3.50 EPS.

Shares of AZN opened at $40.97 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.72 and a quick ratio of 0.54. The company has a market cap of $99.31 billion, a price-to-earnings ratio of 9.57, a P/E/G ratio of 2.09 and a beta of 0.57. AstraZeneca has a 52 week low of $31.99 and a 52 week high of $41.28.

A number of brokerages have commented on AZN. ValuEngine raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Saturday, July 28th. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, July 16th. Guggenheim began coverage on AstraZeneca in a report on Monday, October 8th. They set a “buy” rating for the company. Wolfe Research began coverage on AstraZeneca in a report on Tuesday, October 23rd. They set an “outperform” rating for the company. Finally, Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. AstraZeneca currently has an average rating of “Buy” and an average price target of $40.34.

In related news, major shareholder Plc Astrazeneca acquired 246,666 shares of the firm’s stock in a transaction on Friday, September 28th. The stock was purchased at an average cost of $15.00 per share, with a total value of $3,699,990.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Hedge funds and other institutional investors have recently made changes to their positions in the company. HPM Partners LLC boosted its stake in shares of AstraZeneca by 50.2% in the 2nd quarter. HPM Partners LLC now owns 34,813 shares of the company’s stock worth $1,222,000 after buying an additional 11,629 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of AstraZeneca in the 2nd quarter worth approximately $10,519,000. Vident Investment Advisory LLC boosted its stake in shares of AstraZeneca by 30.5% in the 2nd quarter. Vident Investment Advisory LLC now owns 69,090 shares of the company’s stock worth $2,426,000 after buying an additional 16,137 shares during the last quarter. Baird Financial Group Inc. boosted its stake in shares of AstraZeneca by 12.0% in the 2nd quarter. Baird Financial Group Inc. now owns 56,959 shares of the company’s stock worth $2,000,000 after buying an additional 6,092 shares during the last quarter. Finally, Argent Trust Co purchased a new position in shares of AstraZeneca in the 2nd quarter worth approximately $536,000. Hedge funds and other institutional investors own 16.10% of the company’s stock.

WARNING: “AstraZeneca (AZN) Issues Earnings Results” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/10/astrazeneca-azn-issues-earnings-results.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: What is the float in trading stocks?

Earnings History for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.